Completed PHASE3 INTERVENTIONAL 2-arm NCT00794573

Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial (EVITA)

Sponsor: Mark Eisenberg

Updated 8 times since 2017 Last updated: Apr 26, 2019 Started: Sep 30, 2009 Primary completion: Jun 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00794573, this PHASE3 trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by Mark Eisenberg, it has been updated 8 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Oct 2021 [monthly]

Completed PHASE3
Jun 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jun 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mark Eisenberg
Queen Elizabeth II Health Sciences Centre
Sunnybrook Health Sciences Centre
Unity Health Toronto

Data source: McGill University

For direct contact, visit the study record on ClinicalTrials.gov .

Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial (EVITA)

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials